Indoco Remedies Ltd. announced today, that its Clinical Research Organisation, AnaCipher, located at Hyderabad successfully cleared the United States Food and Drug Administration (USFDA) inspection with zero 483s. The inspection was held from 14th October to 18th October, 2019.
Commenting on this development, Ms. Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited said, "This achievement is for the fifth time in a row and confirms the capabilities of our team at the CRO for maintaining highest quality standards and excellence in servicing our clients".
The CRO - AnaCipher conducts Bio-Equivalence and Bio-Availability (BA/BE) studies at its facility in Hyderabad and is spread over an area of 30,000 sq. ft. with 98 beds.
Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.143.7 as compared to the previous close of Rs. 140.55. The total number of shares traded during the day was 1386 in over 57 trades.
The stock hit an intraday high of Rs. 146.5 and intraday low of 141.15. The net turnover during the day was Rs. 200034.